Avadel Pharmaceuticals plc (AVDL)

NASDAQ: AVDL · IEX Real-Time Price · USD
13.72
+0.94 (7.36%)
At close: Mar 1, 2024, 4:00 PM
14.10
+0.38 (2.77%)
After-hours: Mar 1, 2024, 7:59 PM EST
7.36%
Market Cap 1.23B
Revenue (ttm) 27.96M
Net Income (ttm) -160.28M
Shares Out 89.40M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,119,457
Open 12.79
Previous Close 12.78
Day's Range 12.36 - 13.86
52-Week Range 8.00 - 17.24
Beta 1.57
Analysts Strong Buy
Price Target 21.00 (+53.06%)
Earnings Date Mar 4, 2024

About AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. [Read more]

Sector Healthcare
IPO Date Jun 7, 1996
Employees 41
Stock Exchange NASDAQ
Ticker Symbol AVDL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for AVDL stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 53.06% from the latest price.

Price Target
$21.0
(53.06% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

-- $7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch -- -- Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUP TM and more than 400 patien...

4 months ago - GlobeNewsWire

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023

– 17 abstracts accepted, including new and encore data emphasizing clinical benefit and patient preference for a once-at-bedtime narcolepsy treatment option –

4 months ago - GlobeNewsWire

Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit

DUBLIN, Ireland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that mem...

5 months ago - GlobeNewsWire

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that mem...

6 months ago - GlobeNewsWire

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

-- Successfully commenced U.S. commercial launch of LUMRYZ™ -- -- Received final FDA approval for LUMRYZ with orphan drug exclusivity granted through May 1, 2030 --

7 months ago - GlobeNewsWire

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9

DUBLIN, Ireland, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it ...

7 months ago - GlobeNewsWire

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, July 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Comm...

8 months ago - GlobeNewsWire

Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII

DUBLIN, Ireland, June 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it ...

9 months ago - GlobeNewsWire

Avadel Pharmaceuticals Sponsors the Academy of Sleep Medicine Foundation's 2023 Young Investigators Research Forum

DUBLIN, Ireland, June 14, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced leader sponsorship of the ...

9 months ago - GlobeNewsWire

Avadel Pharmaceuticals Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-at-Bedtime Oxybate Dosing for Narcolepsy

Among 100 clinicians, the primary driver of overall oxybate choice, potential to improve patient quality of life, and decrease stress/anxiety was a single bedtime dose over the twice-nightly dosing of...

9 months ago - GlobeNewsWire

Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ™ (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy

-LUMRYZ is the first and only once-at-bedtime oxybate for people living with narcolepsy -Once-nightly dosing regimen of LUMRYZ has been found by FDA to provide a major contribution to patient care ove...

9 months ago - GlobeNewsWire

Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference

DUBLIN, Ireland, June 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that mem...

9 months ago - GlobeNewsWire

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

– 12 accepted abstracts highlight Company's emerging leadership in narcolepsy – – Data adds to growing body of evidence demonstrating positive clinical benefit and patient preference of once-at-bedtim...

9 months ago - GlobeNewsWire

Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy

- Granted Orphan Drug Exclusivity through May 1, 2030 - -Advanced commercial preparations on track; LUMRYZ product availability expected in early June - - Final approval supported by robust efficacy a...

10 months ago - GlobeNewsWire

Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference

DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that me...

11 months ago - GlobeNewsWire

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

• LUMRYZ™ NDA amendment filed March 1 requesting FDA final approval

1 year ago - GlobeNewsWire

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it...

1 year ago - GlobeNewsWire

Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced to...

1 year ago - GlobeNewsWire

Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced to...

1 year ago - GlobeNewsWire

Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million

– In parallel, extended maturity on $96.2 million of convertible notes to April 1, 2027

1 year ago - GlobeNewsWire

Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision

Importation of LUMRYZ to the U.S. shortens the time to product availability following a final approval decision Importation of LUMRYZ to the U.S. shortens the time to product availability following a ...

1 year ago - GlobeNewsWire

Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

DUBLIN, Ireland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that mem...

1 year ago - GlobeNewsWire

Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybates

- Adverse events were reported in patients who took the second, middle-of-the-night dose of immediate-release oxybate less than 2.5 hours after the first dose -

1 year ago - GlobeNewsWire

Avadel Pharmaceuticals Announces Favorable Ruling on Motion to Delist REMS Patent from FDA's Orange Book

- Delisting of REMS Patent sets path to potentially accelerate final approval by FDA

1 year ago - GlobeNewsWire

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results

DUBLIN, Ireland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corpora...

1 year ago - GlobeNewsWire